Literature DB >> 33555331

Assessment of Seroprevalence of SARS-CoV-2 and Risk Factors Associated With COVID-19 Infection Among Outpatients in Virginia.

Elizabeth T Rogawski McQuade1,2, Kristin A Guertin2, Lea Becker1, Darwin Operario1, Jean Gratz1, Dave Guan3, Fauzia Khan3, Jennifer White1, Timothy L McMurry2, Bhruga Shah4, Stephanie Garofalo4, Matt Southerland4, Kelly Bear4, John Brush5, Cynthia Allen5, Amy Frayser6, Rebecca Vokes6, Rashmi Pershad6, Lilian Peake7, Christopher deFilippi4, Kathleen Barackman5, Gonzalo Bearman6, Andrea Bidanset8, Francis Farrell8, David Trump7, Eric R Houpt1.   

Abstract

Importance: Data from seroepidemiologic surveys measuring severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exposure in diverse communities and ascertaining risk factors associated with infection are important to guide future prevention strategies. Objective: To assess the prevalence of previous SARS-CoV-2 infection across Virginia and the risk factors associated with infection after the first wave of coronavirus disease 2019 (COVID-19) infections in the US. Design, Setting, and Participants: In this statewide cross-sectional surveillance study, 4675 adult outpatients presenting for health care not associated with COVID-19 in Virginia between June 1 and August 14, 2020, were recruited to participate in a questionnaire and receive venipuncture to assess SARS-CoV-2 serology. Eligibility was stratified to meet age, race, and ethnicity quotas that matched regional demographic profiles. Main Outcomes and Measures: The main outcome was SARS-CoV-2 seropositivity, as measured by the Abbott SARS-CoV-2 immunoglobulin G assay.
Results: Among 4675 adult outpatients (mean [SD] age, 48.8 [16.9] years; 3119 women [66.7%]; 3098 White [66.3%] and 4279 non-Hispanic [91.5%] individuals) presenting for non-COVID-19-associated health care across Virginia, the weighted seroprevalence was 2.4% (95% CI, 1.8%-3.1%) and ranged from 0% to 20% by zip code. Seroprevalence was notably higher among participants who were Hispanic (10.2%; 95% CI, 6.1%-14.3%), residing in the northern region (4.4%; 95% CI, 2.8%-6.1%), aged 40 to 49 years (4.4%; 95% CI, 1.8%-7.1%), and uninsured (5.9%; 95% CI, 1.5%-10.3%). Higher seroprevalence was associated with Hispanic ethnicity (adjusted odds ratio [aOR], 3.56; 95% CI, 1.76-7.21), residence in a multifamily unit (aOR, 2.55; 95% CI, 1.25-5.22), and contact with an individual with confirmed COVID-19 infection (aOR, 4.33; 95% CI, 1.77-10.58). The sensitivity of serology results was 94% (95% CI, 70%-100%) among those who reported receiving a previous polymerase chain reaction test for COVID-19 infection. Among 101 participants with seropositive results, 67 individuals (66.3%) were estimated to have asymptomatic infection. These data suggested a total estimated COVID-19 burden that was 2.8-fold higher than that ascertained by PCR-positive case counts. Conclusions and Relevance: This large statewide serologic study estimated that 2.4% of adults in Virginia had exposure to SARS-CoV-2, which was 2.8-fold higher than confirmed case counts. Hispanic ethnicity, residence in a multifamily unit, and contact with an individual with confirmed COVID-19 infection were significant risk factors associated with exposure. Most infections were asymptomatic. As of August 2020, the population in Virginia remained largely immunologically naive to the virus.

Entities:  

Year:  2021        PMID: 33555331     DOI: 10.1001/jamanetworkopen.2020.35234

Source DB:  PubMed          Journal:  JAMA Netw Open        ISSN: 2574-3805


  17 in total

1.  Prevalence of SARS-CoV-2 antibodies and risk factors in the pandemic epicentre of Catalonia.

Authors:  Sandra Moreno; Queralt Miró; Ainhoa Soler; Mireia Gallego; Maria Homs; Maria José Garcia
Journal:  Sci Rep       Date:  2022-06-02       Impact factor: 4.996

2.  Ethnoracial Disparities in SARS-CoV-2 Seroprevalence in a Large Cohort of Individuals in Central North Carolina from April to December 2020.

Authors:  Cesar A Lopez; Clark H Cunningham; Sierra Pugh; Katerina Brandt; Usaphea P Vanna; Matthew J Delacruz; Quique Guerra; D Ryan Bhowmik; Samuel J Goldstein; Yixuan J Hou; Margaret Gearhart; Christine Wiethorn; Candace Pope; Carolyn Amditis; Kathryn Pruitt; Cinthia Newberry-Dillon; John L Schmitz; Lakshmanane Premkumar; Adaora A Adimora; Ralph S Baric; Michael Emch; Ross M Boyce; Allison E Aiello; Bailey K Fosdick; Daniel B Larremore; Aravinda M de Silva; Jonathan J Juliano; Alena J Markmann
Journal:  mSphere       Date:  2022-05-19       Impact factor: 5.029

3.  Prevalence of Anti-SARS-CoV-2 Antibodies in Poznań, Poland, after the First Wave of the COVID-19 Pandemic.

Authors:  Dagny Lorent; Rafal Nowak; Carolina Roxo; Elzbieta Lenartowicz; Aleksandra Makarewicz; Bartosz Zaremba; Szymon Nowak; Lukasz Kuszel; Jerzy Stefaniak; Ryszard Kierzek; Pawel Zmora
Journal:  Vaccines (Basel)       Date:  2021-05-21

4.  Seropositivity of COVID-19 among asymptomatic healthcare workers: A multi-site prospective cohort study from Northern Virginia, United States.

Authors:  Abdulla A Damluji; Siqi Wei; Scott A Bruce; Amanda Haymond; Emanuel F Petricoin; Lance Liotta; G Larry Maxwell; Brian C Moore; Rachel Bell; Stephanie Garofalo; Eric R Houpt; David Trump; Christopher R deFilippi
Journal:  Lancet Reg Health Am       Date:  2021-07-29

5.  SARS-CoV-2 antibody seroprevalence in Lebanon: findings from the first nationwide serosurvey.

Authors:  Abbas Hoballah; Rana El Haidari; Ghina Siblany; Fadi Abdel Sater; Samir Mansour; Hamad Hassan; Linda Abou-Abbas
Journal:  BMC Infect Dis       Date:  2022-01-10       Impact factor: 3.090

Review 6.  Performance Evaluation of Lateral Flow Assays for Coronavirus Disease-19 Serology.

Authors:  Lucy Ochola; Paul Ogongo; Samuel Mungai; Jesse Gitaka; Sara Suliman
Journal:  Clin Lab Med       Date:  2021-11-03       Impact factor: 1.935

7.  Association between COVID-19 Risk-Mitigation Behaviors and Specific Mental Disorders in Youth.

Authors:  Kevin P Conway; Kriti Bhardwaj; Emmanuella Michel; Diana Paksarian; Aki Nikolaidis; Minji Kang; Kathleen R Merikangas; Michael P Milham
Journal:  medRxiv       Date:  2022-03-05

8.  SARS-CoV-2 Period Seroprevalence and Related Factors, Hillsborough County, Florida, USA, October 2020-March 2021.

Authors:  Anna R Giuliano; Shari Pilon-Thomas; Michael J Schell; Martha Abrahamsen; Jessica Y Islam; Kimberly Isaacs-Soriano; Kayoko Kennedy; Christopher W Dukes; Junmin Whiting; Julie Rathwell; Jonathan A Hensel; Leslie N Mangual; Ernst Schonbrunn; Melissa Bikowitz; Dylan Grassie; Yan Yang
Journal:  Emerg Infect Dis       Date:  2022-01-26       Impact factor: 6.883

9.  Disparities in SARS-CoV-2 seroprevalence among individuals presenting for care in central North Carolina over a six-month period.

Authors:  Cesar A Lopez; Clark H Cunningham; Sierra Pugh; Katerina Brandt; Usaphea P Vanna; Matthew J Delacruz; Quique Guerra; Samuel Jacob Goldstein; Yixuan Jacob Hou; Margaret Gearhart; Christine Wiethorn; Candace Pope; Carolyn Amditis; Kathryn Pruitt; Cinthia Newberry-Dillon; John Schmitz; Lakshmanane Premkumar; Adaora A Adimora; Michael Emch; Ross Boyce; Allison E Aiello; Bailey K Fosdick; Daniel B Larremore; Aravinda M de Silva; Jonathan J J Juliano; Alena J Markmann
Journal:  medRxiv       Date:  2021-03-30

10.  Substance use disorders and COVID-19: An analysis of nation-wide Veterans Health Administration electronic health records.

Authors:  Deborah S Hasin; David S Fink; Mark Olfson; Andrew J Saxon; Carol Malte; Katherine M Keyes; Jaimie L Gradus; Magdalena Cerdá; Charles C Maynard; Salomeh Keyhani; Silvia S Martins; Ofir Livne; Zachary L Mannes; Scott E Sherman; Melanie M Wall
Journal:  Drug Alcohol Depend       Date:  2022-03-03       Impact factor: 4.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.